Chronic Obstructive Pulmonary Disease
Conditions
Brief summary
Aerosol delivery through a ventilator is influenced by numerous factors from ventilator-related, circuit-related to device-related factors. Aerosolized drug delivery through a ventilator system was studied on bench model with albuterol, yet the results were often overestimated. The objective of this study was to evaluate inhaled bronchodilator and mucolytic agents delivered through a ventilator system.
Detailed description
Aerosolized medication is used widely to patients with respiratory illness and admitted in the intensive care unit, and includes bronchodilators, steroids, mucolytics, and antibiotics. Aerosol delivery through a ventilator is influenced by numerous factors from ventilator-related, circuit-related to device-related factors. Aerosolized drug delivery through a ventilator system was studied on bench model with albuterol, yet the results were often overestimated. Only few clinical trials on aerosol delivery deposition were published in the last decades. In addition, inhaled bronchodilators, mucolytics, antibiotics, and steroids are often administered to ventilated patients in the intensive care units in Taiwan, but they are never studied. Therefore, the aim of this study was to evaluate inhaled bronchodilator and mucolytics (acetylcystine) delivered by a jet nebulizer through a ventilator system to intubated patients.
Interventions
DRUGSalbutamol
Salbutamol (albuterol ) was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
DRUGAcetylcysteine
Acetylcystine was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
Sponsors
Chang Gung Memorial Hospital
Chang Gung University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Mechanical ventilated patients with an endotracheal tube intubated * Receiving aerosol therapy with salbutamol or acetylcystine * On relatively stable medical condition
Exclusion criteria
* Pregnant * Unstable hemodynamic status (e.g. blood pressure \<100/60 mmHg, under Intra-aortic balloon pump) * Infected with airborne pathogens (e.g. tuberculosis or Influenza virus) * Poor oxygenation (fraction of inspiratory oxygen \>0.8, under high frequency oscillatory ventilation, or extracorporeal membrane oxygenation)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Inhaled drug dose | Inhaled drug dose was collected Immediately after each nebulization, expected average of 20 minutes | Drug depositions in inspiratory filters were analyzed by a spectrophotometer. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| exhaled drug dose | Exhaled drug dose was collected Immediately after each nebulization, expected average of 20 minutes | Drug depositions in expiatory filters were analyzed by a spectrophotometer. |
Countries
Taiwan
Outcome results
None listed